AZ’s asthma and diabetes drugs get label boosts in EUTwo of AstraZeneca’s most important drugs have received a boost, after European regulators backed a pen allowing people Share XAZ’s asthma and diabetes drugs get label boosts in EUhttps://pharmaphorum.com/news/azs-asthma-and-diabetes-drugs-get-label-boosts-in-eu/
The science of prevention‘Prevention’ might be the buzzword of the moment in the pharma industry, but what does it actually mean Share XThe science of preventionhttps://pharmaphorum.com/r-d/views-analysis-r-d/the-science-of-prevention/
Diabetic foot ulcer tool ‘could help cut treatment costs’Caring for people with diabetic foot ulcers costs NHS England the region of £1 billion a year, but Share XDiabetic foot ulcer tool ‘could help cut treatment costs’https://pharmaphorum.com/news/diabetic-foot-ulcers-tool-could-help-cut-treatment-costs/
Novo Nordisk builds cardio claim case for oral semaglutideNovo Nordisk’s bid to disrupt the diabetes market with an oral formulation of its GLP-1 agonist semaglutide has Share XNovo Nordisk builds cardio claim case for oral semaglutidehttps://pharmaphorum.com/news/novo-nordisk-builds-cardio-claim-case-for-oral-semaglutide/
Sanofi, Lilly and Novo make cases for diabetes drugs at ADAThe American Diabetes Association (ADA) annual conference has dominated the medical research headlines this weekend as pharma and Share XSanofi, Lilly and Novo make cases for diabetes drugs at ADAhttps://pharmaphorum.com/news/sanofi-lilly-and-novo-diabetes/
Beyond glucose in type 2 diabetes: how Novo Nordisk is looking to address chronic kidney diseaseAfter moving from academia to industry, Stephen Gough is now Novo Nordisk’s global chief medical officer, working on Share XBeyond glucose in type 2 diabetes: how Novo Nordisk is looking to address chronic kidney diseasehttps://pharmaphorum.com/r-d/views-analysis-r-d/beyond-glucose-in-type-2-diabetes-how-novo-nordisk-is-looking-to-address-chronic-kidney-disease/
Drugs could mimic gut bacteria benefits to treat diabetesIt may be possible to design drugs that mimic the positive health benefits of gut bacteria to treat Share XDrugs could mimic gut bacteria benefits to treat diabeteshttps://pharmaphorum.com/news/drugs-gut-bacteria-diabetes/
J&J’s Invokana reduces risk of renal failure in high-risk diabetes patientsJohnson & Johnson’s Janssen pharma unit has announced new results showing that its Invokana diabetes medicine is the Share XJ&J’s Invokana reduces risk of renal failure in high-risk diabetes patientshttps://pharmaphorum.com/news/jjs-invokana-reduces-risk-of-renal-failure-in-high-risk-diabetes-patients/
PBM cuts insulin co-pay as lawmaker confrontations loomExpress Scripts has announced a plan to cut patient co-pays for insulin products at $25 a month ahead Share XPBM cuts insulin co-pay as lawmaker confrontations loomhttps://pharmaphorum.com/news/pbm-insulin-express-scripts/
